Eliseo Oreste Salinas, M.D., MSc

Eliseo Oreste Salinas, M.D., MSc, Chief Research and Development Officer

Eliseo Oreste Salinas, M.D., MSc, has served as our chief research & development (R&D) officer since March 2021. He joined our company from Acadia Pharmaceuticals, where was chief scientific officer (CSO), senior vice president and head of External Innovation since September 2018. Dr. Salinas has 30 years of experience developing diverse therapeutic products for central nervous system and other disorders, spanning small molecules, biologics and cell therapy. He has been directly involved with numerous investigational new drug (IND) applications and 15 regulatory approvals. For the last 17 years of his career, Dr. Salinas has managed R&D organizations in mid-size companies, such as Shire and Elan Pharmaceuticals, where he was executive vice president, R&D and CSO, and executive vice president, head of development and chief medical officer, respectively. He also has managed R&D at small pharmaceutical and biotechnology companies, including Adolor, StemCell Inc. and New World Laboratories. Dr. Salinas received his M.D. from the University of Buenos Aires, Argentina, completed his residency in psychiatry at the Clinique des Maladies Mentales et de l'Encéphale, Paris, and obtained his Master of Science degree in pharmacology from the Université Pierre et Marie Curie, Académie de Paris.